Theravance Biopharma, Inc.
TBPH
$10.61
$0.000.00%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 65.27M | 64.38M | 63.19M | 62.02M | 61.51M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 65.27M | 64.38M | 63.19M | 62.02M | 61.51M |
| Cost of Revenue | 29.75M | 30.14M | 29.00M | 28.04M | 27.51M |
| Gross Profit | 35.52M | 34.24M | 34.19M | 33.97M | 34.00M |
| SG&A Expenses | 70.80M | 69.17M | 66.52M | 65.79M | 68.01M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 110.93M | 106.82M | 103.03M | 101.34M | 103.03M |
| Operating Income | -45.66M | -42.44M | -39.83M | -39.32M | -41.52M |
| Income Before Tax | -48.35M | -44.61M | -40.69M | -38.22M | -37.19M |
| Income Tax Expenses | 9.98M | 11.80M | 8.71M | 7.43M | 7.58M |
| Earnings from Continuing Operations | -58.33 | -56.42 | -49.40 | -45.65 | -44.77 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -58.33M | -56.42M | -49.40M | -45.65M | -44.77M |
| EBIT | -45.66M | -42.44M | -39.83M | -39.32M | -41.52M |
| EBITDA | -43.62M | -40.37M | -37.80M | -37.28M | -39.03M |
| EPS Basic | -1.19 | -1.15 | -1.01 | -0.92 | -0.86 |
| Normalized Basic EPS | -0.56 | -0.51 | -0.47 | -0.45 | -0.44 |
| EPS Diluted | -1.19 | -1.15 | -1.01 | -0.92 | -0.86 |
| Normalized Diluted EPS | -0.56 | -0.51 | -0.47 | -0.45 | -0.44 |
| Average Basic Shares Outstanding | 196.80M | 195.37M | 195.48M | 198.81M | 206.74M |
| Average Diluted Shares Outstanding | 196.80M | 195.37M | 195.48M | 198.81M | 206.74M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |